An information-intensive approach to the molecular pharmacology of cancer

被引:994
作者
Weinstein, JN
Myers, TG
OConnor, PM
Friend, SH
Fornace, AJ
Kohn, KW
Fojo, T
Bates, SE
Rubinstein, LV
Anderson, NL
Buolamwini, JK
vanOsdol, WW
Monks, AP
Scudiero, DA
Sausville, EA
Zaharevitz, DW
Bunow, B
Viswanadhan, VN
Johnson, GS
Wittes, RE
Paull, KD
机构
[1] FRED HUTCHINSON CANC RES CTR, NCI, SEATTLE, WA 98105 USA
[2] NCI, DIV CLIN SCI, MED BRANCH, NIH, BETHESDA, MD 20892 USA
[3] NCI, DIV CANC TREATMENT DIAGNOSIS & CTR, CANC THERAPY EVALUAT PROGRAM,BIOMETR RES BRANCH, NIH, BETHESDA, MD 20892 USA
[4] LARGE SCALE BIOL, ROCKVILLE, MD 20850 USA
[5] NCI, FREDERICK CANC RES & DEV CTR, SAIC, FREDERICK, MD 21701 USA
[6] NCI, DEV THERAPEUT PROGRAM, DCTDC, NIH, BETHESDA, MD 20892 USA
[7] NCI, INFORMAT TECHNOL BRANCH,DEV THERAPEUT PROGRAM, DCTDC,NIH, BETHESDA, MD 20892 USA
[8] NCI, GRANTS & CONTRACTS OPERAT BRANCH, DEV THERAPEUT PROGRAM,DCTDC,NIH, BETHESDA, MD 20892 USA
[9] NCI, OFF DIRECTOR, DCTDC, NIH, BETHESDA, MD 20892 USA
关键词
D O I
10.1126/science.275.5298.343
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Since 1990, the National Cancer institute (NCI) has screened more than 60,000 compounds against a panel of 60 human cancer cell lines, The 50-percent growth-inhibitory concentration (GI(50)) for any single cell line is simply an index of cytotoxicity or cytostasis, but the patterns of 60 such GI(50) values encode unexpectedly rich, detailed information on mechanisms of drug action and drug resistance. Each compound's pattern is like a fingerprint, essentially unique among the many billions of distinguishable possibilities. These activity patterns are being used in conjunction with molecular structural features of the tested agents to explore the NCI's database of more than 460,000 compounds, and they are providing insight into potential target molecules and modulators of activity in the 60 cell lines, For example, the information is being used to search for candidate anticancer drugs that are not dependent on intact p53 suppressor gene function for their activity. It remains to be seen how effective this information-intensive strategy will be at generating new clinically active agents.
引用
收藏
页码:343 / 349
页数:7
相关论文
共 53 条
[11]  
FAN SJ, 1995, CANCER RES, V55, P1649
[12]  
FAN SJ, 1994, CANCER RES, V54, P5824
[13]   P53 - A GLIMPSE AT THE PUPPET BEHIND THE SHADOW PLAY [J].
FRIEND, S .
SCIENCE, 1994, 265 (5170) :334-335
[14]   BIOCHEMISTRY OF MULTIDRUG-RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER [J].
GOTTESMAN, MM ;
PASTAN, I .
ANNUAL REVIEW OF BIOCHEMISTRY, 1993, 62 :385-427
[15]  
GREENBLATT MS, 1994, CANCER RES, V54, P4855
[16]  
GREVER MR, 1992, SEMIN ONCOL, V19, P622
[17]  
GUPTA M, 1995, MOL PHARMACOL, V48, P658
[18]   Antitumor 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone derivatives - Interactions with tubulin [J].
Hamel, E ;
Lin, CM ;
Plowman, J ;
Wang, HK ;
Lee, KH ;
Paull, KD .
BIOCHEMICAL PHARMACOLOGY, 1996, 51 (01) :53-59
[19]   p53 tumor suppressor gene: From the basic research laboratory to the clinic - An abridged historical perspective [J].
Harris, CC .
CARCINOGENESIS, 1996, 17 (06) :1187-1198
[20]   CELL-CYCLE CONTROL AND CANCER [J].
HARTWELL, LH ;
KASTAN, MB .
SCIENCE, 1994, 266 (5192) :1821-1828